Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pluristem Therapeutc (PSTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 81,776
  • Shares Outstanding, K 145,380
  • Annual Sales, $ 50 K
  • Annual Income, $ -26,130 K
  • 60-Month Beta 0.98
  • Price/Sales 1,628.26
  • Price/Cash Flow N/A
  • Price/Book 9.44
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.25
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/16/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.07
  • Number of Estimates 1
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.55 +1.82%
on 06/07/19
0.73 -23.29%
on 05/21/19
-0.08 (-12.51%)
since 05/17/19
3-Month
0.50 +12.00%
on 04/18/19
1.02 -45.10%
on 03/18/19
-0.43 (-43.66%)
since 03/15/19
52-Week
0.50 +12.00%
on 04/18/19
1.38 -59.42%
on 08/24/18
-0.71 (-55.91%)
since 06/15/18

Most Recent Stories

More News
Pluristem Strengthens Its Manufacturing Competitive Advantage, Presents its First Proprietary Serum-Free Cell Therapy Product

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the Company has developed a serum-free...

PSTI : 0.56 (unch)
Lead Physicians in Pluristem's Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, announced the publication of a peer-reviewed article...

PSTI : 0.56 (unch)
Pluristem Files Patent Application for the Use of its Advanced Manufacturing Technology in the Cannabis Industry

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that it has filed a U.S. provisional...

PSTI : 0.56 (unch)
Recent Analysis Shows OneMain, E*TRADE Financial, Keurig Dr Pepper, and Pluristem Therapeutics Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of OneMain Holdings, Inc. (NYSE:OMF),...

KDP : 29.91 (+4.47%)
OMF : 31.48 (-0.38%)
ETFC : 45.93 (+1.37%)
PSTI : 0.56 (unch)
Pluristem Completes Interim Enrollment in Pivotal CLI Study, Targeting Potential Conditional Marketing Approval in Europe

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced the Company has achieved a significant...

PSTI : 0.56 (unch)
Pluristem Therapeutics Issues Shareholder Update

-- Recent financing provides funding through multiple potentially value-creating milestones

PSTI : 0.56 (unch)
Pluristem Therapeutics Inc. Announces Pricing of Its Public Offering and Registered Direct Offering for Aggregate Proceeds of Approximately $20 Million

Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) ("Pluristem" or "Company"), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today...

PSTI : 0.56 (unch)
Pluristem Therapeutics Inc. Announces Proposed Public Offering of Common Stock and Warrants and Concurrent Registered Direct Offering of Common Stock

Pluristem Therapeutics Inc. (Nasdaq: PSTI, TASE: PLTR) ("Pluristem" or "Company"), a leading regenerative medicine company developing novel placenta-based cell therapy product candidates, announced today...

PSTI : 0.56 (unch)
Pluristem Therapeutics Announces Completion of 2nd Cohort and DSMB Approval to Enroll Final Cohort in Phase I Hematological Study of PLX-R18

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the Company has fully enrolled...

PSTI : 0.56 (unch)
Pluristem Enters into Collaboration with NASA to Study PLX Therapeutic Benefits in Space Missions

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced a collaboration between the company...

PSTI : 0.56 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade PSTI with:

Business Summary

PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use,...

See More

Key Turning Points

2nd Resistance Point 0.58
1st Resistance Point 0.57
Last Price 0.56
1st Support Level 0.56
2nd Support Level 0.55

See More

52-Week High 1.38
Fibonacci 61.8% 1.04
Fibonacci 50% 0.94
Fibonacci 38.2% 0.84
Last Price 0.56
52-Week Low 0.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar